About this content About William Farrington William kickstarted his career as a researcher and reporter for a global legal publication, covering everything from public law to M&A. Before moving to Proactive Investors, he worked as a reporter for a major fintech company with a focus on cryptocurrency and blockchain technology. Harking from Queensland, Australia, William obtained first-class honours in journalism and media from Birkbeck University before going on to complete an MA in creative and critical ...

AbbVie’s (ABBV) mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company lost 12.6% on Monday in response to the disappointing news. However, Bristol Myers’ (BMY) stock was up 10.5% following ABBV’s news.The studies were designed to show a statistically significant reduction (improvement) in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score upon treatment with the candidate compared with the placebo group at week 6 ...

29 April 2024, Rhineland-Palatinate, Ludwigshafen: Malu Dreyer, Minister President of ... [+] Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie. Photo: Uwe Anspach/dpa (Photo by Uwe Anspach/picture alliance via Getty Images)dpa/picture alliance via Getty ImagesAbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clin ...

I last wrote on AbbVie Inc. (NYSE: ABBV ) back in September 2024 and on Pfizer Inc. (NYSE: PFE ) back in August 2024. These articles are titled “AbbVie: Dividend Discount As you can tell, our core style is to provide actionable and unambiguous ideas from our independent research. If your share this investment style, check out Envision Early Retirement. It provides at least 1x in-depth articles per week on such ideas.We have helped our members not only to beat S&P 500 but also avoid heavy drawdowns despite t ...

AbbVie (NYSE: ABBV ) shares are plummeting as the company's schizophrenia treatment drug reportedly failed to meet its primary endpoint in a late-state study. While certainly a blow, the resulting drop of nearly 10% as I write this appears to be significantlyTo follow me click the "Follow" button! (Easy right?) Hi there, thanks for coming to my profile page! My name is Kumquat Research (but you can call me Jeremy) and I've been writing for Seeking Alpha on and off for going on ten years now, beginning with ...

A splashy recent acquisition by the company might not be panning out.Disappointing news from the laboratory weighed on AbbVie (ABBV -12.53%) stock as the trading week kicked off. The company had high hopes for a schizophrenia drug it was developing; however, it did not do well in recent testing. On the company's latest readout, investors were aggressively trading out of the shares, leaving them with a 12% decline in late-afternoon trading.Schizophrenia drug didn't do well in the labJust before the market op ...

关于AbbVie公司试验结果 - AbbVie公司的emraclidine用于成人精神分裂症的两项2期试验失败导致其股票下跌该试验未达到主要终点即与安慰剂组相比在第6周时PANSS总分较基线的变化有统计学意义的改善[1] - 华尔街原本预期AbbVie公司的两项研究有积极结果尽管他们预计细节会有好有坏[2] - 尽管结果消极但Cantor Fitzgerald仍看好AbbVie公司股票并认为其产品线被低估[2] 关于对其他公司影响 - AbbVie令人失望的试验结果对Bristol Myers Squibb公司已获批的精神分裂症药物Cobenfy有利同时也引发了关于使用选择性毒蕈碱靶向治疗精神分裂症和其他疾病的疑问数据可能表明emraclidine等正变构调节剂与Cobenfy等直接激动剂之间存在差异[3] 关于AbbVie公司后续发展 - 尽管遭遇挫折但对Cerevel的收购仍有希望其他治疗方法如Darigabat（用于癫痫和焦虑）和Tavapadon（用于帕金森病）仍在继续进展预计2024年底将获得Tavapadon在帕金森病中的TEMPO - 2期3灵活剂量单药治疗试验的主要结果2025年将获得长期安全性研究TEMPO - 4的结果[4] 关于AbbVie公司股票价格 - 截至周一最后一次检查ABBV股票下跌11.7%至176.16美元[4]

关于AbbVie公司 - AbbVie公司称其精神分裂症药物Emraclidine在两项试验中未达到关键目标后股价周一下跌 [1][2] - 该公司表示在第6周时与安慰剂组相比症状没有显示出统计学上的显著改善 [1][2] - 公司首席科学官Roopal Thakkar称对结果失望并将继续分析数据以确定下一步行动 [2] - 公司股价近期下跌12%今年以来上涨约13% [3] 关于Bristol Myers Squibb公司 - 该公司生产的精神分裂症治疗药物Cobenfy近期获批其股价周一大涨12% [1][3] - 公司股价今年以来已上涨18% [3]

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.AbbVie Inc. (NYSE: ABBV ) announced today that emraclidine failed in bot ...

关于人员 - 威廉·法林顿（William Farrington）的职业生涯始于一家全球法律出版物的研究员和记者，报道内容涵盖公法到并购等领域[1] - 威廉来自澳大利亚昆士兰州，在伯克贝克大学（Birkbeck University）获得新闻与媒体专业一等荣誉学位，之后又完成了创意与批判写作硕士学位[1] 关于出版商 - 出版商Proactive的新闻和在线广播团队为全球投资受众提供快速、易懂、信息丰富且可操作的商业和金融新闻内容，内容由经验丰富且合格的新闻记者团队独立制作[1] - Proactive的新闻团队遍布世界主要金融和投资中心，在伦敦、纽约、多伦多、温哥华、悉尼和珀斯设有办事处和工作室[2] - 公司擅长中小盘市场，也会向大众更新蓝筹公司、大宗商品和更广泛的投资故事[2] - 公司提供包括但不限于生物技术与制药、矿业与自然资源、电池金属、石油与天然气、加密货币以及新兴数字和电动汽车技术等市场的新闻和独特见解[3] 关于技术使用 - Proactive一直是积极采用前瞻性技术的公司，内容创作者拥有数十年宝贵的专业知识和经验，团队也会使用技术来辅助和优化工作流程[3] - 公司偶尔会使用自动化和软件工具，包括生成式人工智能，但所有内容均由人类编辑和撰写，符合内容制作和搜索引擎优化的最佳实践[4]